Talphera Appoints CorMedix CEO Joe Todisco to Board of Directors.
ByAinvest
Tuesday, Oct 21, 2025 8:33 am ET1min read
CRMD--
Todisco, 49, has held senior roles at various pharmaceutical companies, including Amneal Pharmaceuticals and Ranbaxy. He co-founded Gemini Laboratories and holds an MBA in Finance from Fordham Graduate School of Business and a BA in Economics from Georgetown University [1]. His appointment includes a restricted stock unit grant and options to purchase shares of Talphera common stock, vesting over three years [1].
CorMedix's strategic investment provides Talphera with financial support, while also giving CorMedix the right to designate a Talphera board member. Additionally, CorMedix has a 60-day exclusive negotiation period to acquire Talphera following the announcement of key clinical study results for Talphera's Niyad product candidate [2].
Talphera's Niyad, a lyophilized formulation of nafamostat, is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. The company has reached 25% enrollment in its NEPHRO CRRT pivotal clinical trial, with 17 out of 70 patients enrolled [2]. Talphera is navigating market challenges, including supply chain issues impacting the anticoagulation sector, and has reported strategic reductions in operating expenses [1].
TLPH--
• Talphera appoints Joe Todisco as Board of Directors member • Todisco is CEO of CorMedix, which invested in Talphera in September 2025 • CorMedix has right to nominate representative to Talphera Board • CorMedix has 60-day exclusive negotiation period to acquire Talphera
Talphera, Inc. (NASDAQ: TLPH) has appointed Joe Todisco as a Class III director and member of the compensation committee, effective September 12, 2025 [1]. Todisco, who currently serves as the CEO of CorMedix Inc. (NASDAQ: CRMD), brings extensive experience in the pharmaceutical industry to Talphera's board. His appointment follows a strategic investment by CorMedix in Talphera in September 2025, which granted CorMedix the right to nominate a representative to Talphera's board [2].Todisco, 49, has held senior roles at various pharmaceutical companies, including Amneal Pharmaceuticals and Ranbaxy. He co-founded Gemini Laboratories and holds an MBA in Finance from Fordham Graduate School of Business and a BA in Economics from Georgetown University [1]. His appointment includes a restricted stock unit grant and options to purchase shares of Talphera common stock, vesting over three years [1].
CorMedix's strategic investment provides Talphera with financial support, while also giving CorMedix the right to designate a Talphera board member. Additionally, CorMedix has a 60-day exclusive negotiation period to acquire Talphera following the announcement of key clinical study results for Talphera's Niyad product candidate [2].
Talphera's Niyad, a lyophilized formulation of nafamostat, is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. The company has reached 25% enrollment in its NEPHRO CRRT pivotal clinical trial, with 17 out of 70 patients enrolled [2]. Talphera is navigating market challenges, including supply chain issues impacting the anticoagulation sector, and has reported strategic reductions in operating expenses [1].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet